February 1999
Volume 40, Issue 2
Free
Articles  |   February 1999
Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat.
Author Affiliations
  • Y Takehana
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
  • T Kurokawa
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
  • T Kitamura
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
  • Y Tsukahara
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
  • S Akahane
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
  • M Kitazawa
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
  • N Yoshimura
    Discovery Research Laboratory, R&D, Kissei Pharmaceutical Co., Minamiazumi, Japan.
Investigative Ophthalmology & Visual Science February 1999, Vol.40, 459-466. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y Takehana, T Kurokawa, T Kitamura, Y Tsukahara, S Akahane, M Kitazawa, N Yoshimura; Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat.. Invest. Ophthalmol. Vis. Sci. 1999;40(2):459-466.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

PURPOSE: To determine whether tranilast administered to pigmented rats inhibits formation of choroidal neovascularization induced by diode-laser photocoagulation. METHODS: Female Brown Norway rats were used. On day 0, choroidal neovascularization was induced by diode-laser photocoagulation, using a setting of 75 microm spot size, 0.1 second's duration, and 100 mW intensity. Tranilast (200 or 600 mg/kg per day) was administered orally twice daily for 14 days. Indomethacin (1 and 5 mg/kg per day) was administered orally once a day for 14 days. Choroidal neovascularization was evaluated on days 7 and 14 by fundus photography and fluorescein angiography. Late-phase fluorescein angiography was scored according to four grades. The animals were killed on day 14, and the lesions were evaluated histologically. RESULTS: In the vehicle-treated group, 34 of 35 burns (97%) showed fluorescein staining and late leakage on day 14. Choroidal neovascularization was identified by light microscopy in all the lesions that showed fluorescein staining and late leakage. The score of fluorescein staining was reduced in rats given 200 mg/kg per day or 600 mg/kg per day (P < 0.01) of tranilast. The thickness of the laser-induced lesions was reduced in a dose-dependent manner by tranilast, a significant difference was observed with 600 mg/kg per day (P < 0.05). Oral indomethacin treatment did not reduce fluorescein staining on day 14. CONCLUSIONS: Tranilast inhibits the development of choroidal neovascularization in this experimental model.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×